Tariquidar : Xenova Group : P-glycoprotein (P-gp) inhibitor

QLT, Inc. Discontinues Tariquidar Phase III NSCLC Trials Following Interim Analysis by the Independent Data Safety Monitoring Committee (QLT, Inc.)
Press release announcing that QLT, Inc. has stopped its current Phase III tarquidar trials in NSCLC. The decision was made following a recommendation by the Independent Data Safety Monitoring Committee (DSMC) who completed the unblinded review of the data for both ongoing trials in this indication. QLT, Inc. intends to carefully review the interim analysis in order to plan the next steps for tarquidar. [5/03]

Tariquidar - Clinical Trials (ClinicalTrials.gov)